1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 7,300 | 7,550 | 20:49 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - BIOLOGICS LICENSE APPLICATION (BLA) FOR HANBEITAI (BEVACIZUMAB INJECTION) HAS BEEN ACCEPTED BY THE UNITED STATES ... | 1 | HKEx | ||
| SHANGHAI HENLIUS BIOTECH Aktie jetzt für 0€ handeln | |||||
| 31.12.25 | HENLIUS (02696): POLL RESULTS OF THE RESOLUTION PROPOSED AT THE 2025 FOURTH EXTRAORDINARY GENERAL MEETING HELD ON WEDNESDAY, 31 DECEMBER 2025 | 3 | HKEx | ||
| 31.12.25 | HENLIUS (02696): CONTINUING CONNECTED TRANSACTIONS | 1 | HKEx | ||
| 29.12.25 | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT HAS BEEN DOSED IN A PHASE 1 CLINICAL STUDY OF HLX37 (RECOMBINANT HUMANISED ANTI-PD-L1 AND ... | 4 | HKEx | ||
| 23.12.25 | Henlius CEO Dr. Jason Zhu to Deliver a Keynote Presentation at JPM 2026 | 678 | PR Newswire | SHANGHAI, Dec. 23, 2025 /PRNewswire/ -- The 44th J.P. Morgan Healthcare Conference will take place from January 12 to 15, 2026, in San Francisco, USA. Dr. Jason Zhu, Executive Director and... ► Artikel lesen | |
| 19.12.25 | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE INVESTIGATIONAL NEW DRUG APPLICATION FOR THE PHASE 1 CLINICAL TRIAL OF NIVOLUMAB BIOSIMILAR HLX18 (RECOMBINANT ... | 4 | HKEx | ||
| 12.12.25 | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION (NDA) FOR HANSIZHUANG (SERPLULIMAB INJECTION) IN COMBINATION WITH CHEMOTHERAPY FOR NEO-/ ... | 1 | HKEx | ||
| 09.12.25 | Alligator Bioscience Comments on Henlius Receiving Regulatory Approval in China to Initiate Phase 2/3 Trials of HLX22 in HER2-Positive Breast Cancer | 329 | ACCESS Newswire | LUND, SE / ACCESS Newswire / December 9, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX)(STO:ATORX) today comments on the announcement by Shanghai Henlius Biotech, Inc. that applications for Phase... ► Artikel lesen | |
| 09.12.25 | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - APPLICATIONS FOR PHASE 2/3 CLINICAL TRIALS OF HLX22 (RECOMBINANT HUMANISED ANTI-HER2 MONOCLONAL ANTIBODY INJECTION) ... | 1 | HKEx | ||
| 03.12.25 | HENLIUS (02696): PROXY FORM FOR THE 2025 FOURTH EXTRAORDINARY GENERAL MEETING TO BE HELD ON 31 DECEMBER 2025 (OR ANY ADJOURNMENT THEREOF) | - | HKEx | ||
| 03.12.25 | HENLIUS (02696): NOTICE OF EXTRAORDINARY GENERAL MEETING | 1 | HKEx | ||
| 03.12.25 | HENLIUS (02696): CONTINUING CONNECTED TRANSACTIONS RENEWAL OF THE SINOPHARM DISTRIBUTION COLLABORATION AND NOTICE OF EXTRAORDINARY GENERAL MEETING | 2 | HKEx | ||
| 03.12.25 | HENLIUS (02696): CONTINUING CONNECTED TRANSACTIONS - RENEWAL OF THE SINOPHARM DISTRIBUTION COLLABORATION | 1 | HKEx | ||
| 03.12.25 | HENLIUS (02696): CONNECTED TRANSACTION AND CONTINUING CONNECTED TRANSACTIONS - COLLABORATION AGREEMENTS WITH AVANC PHARMA FOR FOVINACICLIB CITRATE CAPSULES | - | HKEx | ||
| 02.12.25 | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION (NDA) FOR BIOSIMILAR OF DENOSUMAB HLX14 (RECOMBINANT ANTI-RANKL HUMAN MONOCLONAL ANTIBODY ... | 2 | HKEx | ||
| 01.12.25 | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE INVESTIGATIONAL NEW DRUG APPLICATION OF HLX37 (RECOMBINANT HUMANISED ANTI-PD-L1 AND ANTI-VEGF BISPECIFIC ... | - | HKEx | ||
| 25.11.25 | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - FIRST PATIENT HAS BEEN DOSED IN AN INTERNATIONAL MULTICENTER PHASE 1 CLINICAL STUDY OF IPILIMUMAB BIOSIMILAR ... | 1 | HKEx | ||
| 20.11.25 | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - HANSIZHUANG (SERPLULIMAB INJECTION) IN COMBINATION WITH CHEMOTHERAPY FOR NEO-/ADJUVANT TREATMENT FOR GASTRIC ... | - | HKEx | ||
| 18.11.25 | Organon & Co.: Henlius und Organon geben die Zulassung von POHERDY (Pertuzumab-dpzb) durch die US-amerikanische Arzneimittelbehörde FDA bekannt, dem ersten PERJETA (Pertuzumab)-Biosimilar in den USA | 718 | Business Wire | Shanghai Henlius Biotech, Inc. (2696.HK) und Organon (NYSE: OGN) gaben heute bekannt, dass die US-amerikanische Arzneimittelbehörde FDA (Food and Drug Administration) den Antrag auf Zulassung von... ► Artikel lesen | |
| 17.11.25 | Henlius and Organon score first US Perjeta biosimilar approval | 18 | Pharmaceutical Technology |
1 2 3 4 Weiter >>
69 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,690 | +0,68 % | PTA-NVR: QIAGEN N.V.: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG | DJ PTA-NVR: QIAGEN N.V.: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG
Gesamtstimmrechte gemäß -- 41 WpHG
QIAGEN N.V.: Veröffentlichung der Gesamtzahl der Stimmrechte nach... ► Artikel lesen | |
| BIONTECH | 93,65 | +1,74 % | mRNA Patentstreit: Bayer zieht BioNTech, Pfizer und Moderna vor Gericht | © Foto: Juan Vega - EUROPA PRESSBayer erhebt schwere Patentvorwürfe gegen die Hersteller der erfolgreichsten Corona-Impfstoffe. Im Zentrum steht eine mRNA-Technologie aus den 1980er-Jahren.Der Agrar-... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 82,32 | +5,65 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity | SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| ALUMIS | 24,400 | +10,36 % | Alumis Inc.: Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with... ► Artikel lesen | |
| ERASCA | 8,350 | +11,26 % | Erasca, Inc.: Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones | Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with promising safety and pharmacokinetics data, observed for... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 303,00 | +7,89 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy | BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,725 | +0,75 % | RECURSION PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| COGENT BIOSCIENCES | 37,810 | +7,17 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio | New Drug Application (NDA) for NonAdvSM submitted in December 2025, NDA submission for AdvSM on track for 1H 2026NDA submission for GIST on track for April 2026; bezuclastinib has the potential to... ► Artikel lesen | |
| EVOTEC | 6,406 | -2,23 % | US-Tochter von Evotec erhält neue Förderung von Gates-Stiftung | DJ US-Tochter von Evotec erhält neue Förderung von Gates-Stiftung
DOW JONES--Die US-Tochter des Hamburger Biotechunternehmens Evotec hat neue Fördermittel von der Gates-Stiftung erhalten. Die Investition... ► Artikel lesen | |
| CG ONCOLOGY | 54,94 | +4,39 % | CG Oncology Inc.: CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC | - PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule - First randomized registrational trial... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 27,670 | +10,90 % | Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026 | - Advancing robust clinical pipeline of novel therapeutics for muscular dystrophies and serious cardiac conditions -
- Presenting at the 44th Annual J.P. Morgan... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,550 | +4,40 % | Summit Therapeutics: H.C. Wainwright bestätigt "Buy"-Rating und Kursziel von 40 US-Dollar | ||
| BEAM THERAPEUTICS | 35,120 | +1,65 % | AKTIONÄR-Tipp Beam Therapeutics wie entfesselt: Die Hintergründe! | Innerhalb der Biotech-Branche zählt der Bereich Gen-Schere zu den absoluten Top-Trends. Neben der wohlbekanntesten seiner Klasse, CRISPR/Cas9, entwickeln sich auch andere Ansätze weiter. Dazu zählt... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,51 | +0,08 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| VERA THERAPEUTICS | 48,690 | -0,84 % | Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy | FDA assigned PDUFA target action date of July 7, 2026.If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN.Atacicept received FDA Breakthrough Therapy... ► Artikel lesen |
SHANGHAI HENLIUS BIOTECH INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -2,00 % bei einem Aktienkurs von 7,350 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHANGHAI HENLIUS BIOTECH INC finden Sie auf Wallstreet Online.